Sequent Scientific Ltd (VIYASH) Q4FY26 Management Mirror - Mar-2026 Qtr
Revenue & Overall Growth Outlook
Management upgraded its long-term revenue aspirations, guiding for ~15% top-line growth to reach an EBITDA run-rate of INR 1,000 crores in the next 2-3 years, accelerating from prior targets. In the Dec'25 Qtr, management expressed comfort in reaching an INR 4,000 crore revenue target with 20% EBITDA margins by FY27, ahead of the original FY28 timeline. [Status: Upgraded]
7 more themes on the ELITE plan.